On March 31, 2020, California Gov. Gavin Newsom extended the statewide shelter-in-place order through May 3, 2020. Additional restrictions designed to help protect citizens from the COVID-19 pandemic also were imposed.
Consistent with the March 19 order, this order considers life science companies such as Antibody Solutions to be “essential,” meaning we are exempt from many restrictions imposed on other businesses and can continue our operations. As specified in this order, we are preparing an updated document formalizing the social distancing protocol we had implemented in accordance with the first order.
Because we prioritize the safety of our employees and their families and friends, we already had implemented social distancing, health and safety policies and procedures governing how work was to be conducted in our facility immediately after the March 31 directive. Our policy indicates how many employees can be present in our facility at the same time, and also established additional sanitation and cleaning processes. Employees are allowed to work remotely and have been provided the resources they need to work from home during the shelter-in-place order.
Antibody Solutions continues to closely monitor the situation and any potential impact on our operations or client projects. We’re striving to ensure that all of our ongoing initiatives can and do progress and are staying in contact with our suppliers to ensure that we have all the materials needed. At this point, thankfully, we have not seen a significant impact on our supply chain.
If you have questions, please reach out to your project manager directly or simply call our main line at +1 (650) 938-4300 and use the automated phone tree. During this time, your call will be automatically routed to the mobile phone of the employee you selected.
Thank you for your patience and understanding during these unprecedented times. We’re grateful to have you as part of the Antibody Solutions family, and we appreciate your continued confidence.
We again send wishes that you and your family, friends and colleagues stay safe and secure. While these are, to put it mildly, “unchartered waters” we are all navigating, we are confident that we can and will successfully get through this together.
Author of more than 40 publications, John’s current research interests include new technologies for improving therapeutic antibody discovery, properties of next-generation antibody-like molecules, and best practices for critical reagents used in biologics development.